Abstract
Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches.
A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m
2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented.
Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.